Alzamend Neuro, Inc.

Equities

ALZN

US02262M4078

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7195 ^USD	+2.79%		+6.51%	-19.16%

Mar. 25	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
Jan. 31	Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	CI

Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023

September 13, 2023 at 05:09 pm EDT

Alzamend Neuro, Inc. reported earnings results for the first quarter ended July 31, 2023. For the first quarter, the company reported net loss was USD 3.53 million compared to USD 3.04 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.45 a year ago.

Latest news about Alzamend Neuro, Inc.

Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 25	CI
Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	Jan. 30	CI
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman	Jan. 05	CI
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 15	CI
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	Dec. 11	CI
Alzamend Neuro Receives FDA Approval to Proceed With Phase 2A Study of AL001 Depression Treatment Candidate	Nov. 20	MT
Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment	Nov. 20	DJ
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	Nov. 20	CI
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001	Nov. 13	CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	23-10-30	MT
Alzamend Neuro Seeks FDA Nod to Start Trial in Major Depressive Disorder	23-10-23	MT
Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001	23-10-23	CI
Alzamend Neuro, Inc Receives FDA ?Study May Proceed? Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients	23-10-02	CI
Alzamend Neuro Secures Extension to Regain Compliance With Nasdaq's Minimum Bid Price Rule	23-09-25	MT
Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-13	CI
Alzamend Neuro Files New Drug Application With FDA to Begin Bipolar Disorder Study of Investigational Therapy AL001	23-08-30	MT
Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	23-07-27	CI
Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001	23-06-22	CI
Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	23-04-12	MT
Alzamend Neuro Launches Phase 1/2a Trial of Vaccine Candidate to Treat Dementia Linked to Alzheimer's	23-04-03	MT
Alzamend Neuro, Inc Announces the Initiation of A Phase I/Iia Trial for Its Immunotherapy Vaccine to Treat Mild to Moderate Dementia of the Alzheimer’S Type	23-04-03	CI
Alzamend Neuro, Inc. Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's	23-03-22	CI
Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	23-03-15	CI
Top Premarket Decliners	23-03-06	MT
Alzamend Neuro Partners with Biorasi to Conduct A First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/Iia Clinical Trial	23-01-04	CI

Chart Alzamend Neuro, Inc.

Duration

Period

More charts

Company Profile

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâs immunological system to combat Alzheimer's through a royalty-bearing exclusive worldwide license from the Licensor.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7195 USD

Average target price

21 USD

Spread / Average Target

+2,818.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALZAMEND NEURO, INC.	-19.16%	4.94M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research